The estimated Net Worth of Gregory Gene Freitag is at least $8.77 Million dollars as of 4 June 2024. Mr. Freitag owns over 11,904 units of Axogen stock worth over $3,764,853 and over the last 14 years he sold AXGN stock worth over $4,146,332. In addition, he makes $856,645 as Director at Axogen.
Gregory has made over 30 trades of the Axogen stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 11,904 units of AXGN stock worth $158,085 on 4 June 2024.
The largest trade he's ever made was exercising 125,000 units of Axogen stock on 29 May 2020 worth over $437,500. On average, Gregory trades about 13,372 units every 79 days since 2010. As of 4 June 2024 he still owns at least 283,498 units of Axogen stock.
You can see the complete history of Mr. Freitag stock trades at the bottom of the page.
Gregory Gene Freitag J.D., CPA serves as Director of the Company. Mr. Freitag, JD, CPA, has been Axogen’s General Counsel and a member of our Board of Directors since September 2011. He was Axogen’s Chief Financial Officer from September 2011 to May 2014 and August 2015 to March 2016, and its Senior Vice President Business Development from May 2014 to October 2018. He was Chief Executive Officer, Chief Financial Officer and a board member of LecTec Corporation, an IP licensing and holding company that merged with Axogen in September 2011, from June 2010 through September 2011. From May 2009 to the present, Mr. Freitag has been a principal of FreiMc, LLC, a healthcare and life science consulting and advisory firm he founded that provides strategic guidance and business development advisory services. Prior to founding FreiMc, LLC, Mr. Freitag was a Director of Business Development at Pfizer Health Solutions, a former subsidiary of Pfizer, Inc., from January 2006 to May 2009. From July 2005 to January 2006, Mr. Freitag worked for Guidant Corporation in its business development group. Prior to Guidant Corporation, Mr. Freitag was the Chief Executive Officer of HTS Biosystems, a biotechnology tools start-up company, from March 2000 until its sale in early 2005. Mr. Freitag was the Chief Operating Officer, Chief Financial Officer and General Counsel of Quantech, Ltd., a public point of care diagnostic company, from December 1995 to March 2000. Prior to that time, Mr. Freitag practiced corporate law in Minneapolis, Minnesota. Mr. Freitag is also a director of PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical stage biopharmaceutical company developing immunotherapies for cancer and other disease areas such as infectious disease. Mr. Freitag holds a JD from the University of Chicago and a BA Economics & Business and Law & Society from Macalester College, Minnesota.
As the Director of Axogen, the total compensation of Gregory Freitag at Axogen is $856,645. There are 2 executives at Axogen getting paid more, with Eric Sandberg having the highest compensation of $1,113,440.
Gregory Freitag is 60, he's been the Director of Axogen since 2020. There are 5 older and 10 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.
Gregory's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels und Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: